AI in drug development is moving beyond “failure prevention” into something much bigger: redesigning how we discover, develop, and deliver medicines. In this episode, Dr Andree Bates speaks with Vitalay Fomin of Numenos about biomarker discovery, patient stratification, and why the next breakthroughs come from breaking down data silos across diseases, modalities, and even species.

Vitalay shares his background across biotech and pharma, including work in biomarker discovery, translational medicine, and data science, and how frustration with existing approaches led her to build a new architecture for clinical genomic insights. A core theme is that traditional methods often oversimplify biology by forcing outcomes into binary labels and treating each disease area as an isolated box, even when the available data is too limited to answer meaningful questions well.

Click here to listen to our podcast on Spotify and explore how it works.